Be prepared to monitor and respond
FDA has identified specific groups who face unacceptable health risks from GLP-1 therapy, and PlexusDx screens all patients to ensure safe eligibility before starting treatment
McCormick N, Yokose C, Lu N, Wexler DJ, Avina-Zubieta JA, De Vera MA, McCoy RG, Choi HK
10.1038/s41598-017-17718-y Sci
This is the first time that either DMRS or combined FDG-PET and rs-fMRI have been used in GLP-1R-related studies, as previous studies on GLP-1R have mainly focused on changes in pancreatic and peripheral blood glucose
If plan sponsors decide to cover these medications for weight loss, they should consider implementing a broader health and wellness strategy, one that includes diet exercise, and behavior changes for best long-term results